E2086
- Generic Name
- E2086
Eisai Advances LEQEMBI Subcutaneous and IV Maintenance Dosing Applications for Alzheimer's Disease
• Eisai has initiated a rolling submission to the FDA for a subcutaneous autoinjector of LEQEMBI for weekly maintenance dosing in early Alzheimer's disease, following Fast Track designation.
• A supplemental Biologics License Application (sBLA) has been submitted to the FDA for monthly intravenous (IV) maintenance dosing of LEQEMBI.
• Eisai has begun screening for a study assessing E2086, a novel selective orexin-2 receptor, for the treatment of narcolepsy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath